Production Assistant

McCormick & Company, a US food and flavourings maker, plans to acquire at least 76.55% of Unilever Pakistan Foods Limited and take control of the company. The announcement, dated October 21, was filed through Arif Habib Limited, the manager to the offer. McCormick intends to buy 4,876,294 shares by agreement. The number of shares in a later public offer has not been set. The deal is part of a March 31, 2026 agreement under which McCormick would take sole control of substantially all of Unilever PLC's global food business. It needs regulatory approvals, including from the Competition Commission of Pakistan, and may be withdrawn without them. The combined group would have nearly $20 billion in annual revenue. Its brands would include Knorr, Hellmann's, French's, and Cholula.

Forward Consumer Partners to acquire Welly. Created in 2018 by serial entrepreneur Eric Ryan, Welly is a disruptive consumer healthcare brand built on the premise that cuts and scrapes are proof of a life well-lived. October 19, 2026. 1:53 PM GREENWICH, Conn. - Forward Consumer Partners (Forward) today announced that it has signed an agreement to acquire Welly Health PBC, a leading first-aid and bandage brand, from Unilever. Created in 2018 by serial entrepreneur Eric Ryan, Welly is a disruptive consumer healthcare brand built on the premise that cuts and scrapes are proof of a life well-lived. Today, Welly offers a full range of first aid products designed to clean, protect, and heal a variety of everyday injuries. Welly marks Forward's eighth investment since its inception in 2023. Matt Leeds, Forward's Founder and Managing Partner, remarked: "Welly is a textbook Forward asset: a powerful brand that makes beloved products, with an enduring track record of success and significant untapped potential. This investment also expands Forward's reach into new sectors of the fast-moving consumer goods landscape, marking our first consumer health investment. We are honored to be entrusted with the next chapter of the Welly story." Brandon Staub, partner at Forward, added: "Welly is a beloved consumer brand, and this transaction represents Forward's approach to working with large strategics around powerful assets with significant opportunity ahead. Our ability to move with speed and integrity during transactions creates a template for many other such partnerships in the future. We are inspired by the opportunity that lies ahead for Welly and are excited to help the company make progress toward its potential." Concurrent with closing, Forward is thrilled to announce that Eric Ryan will return to the business as a strategic advisor and member of the board of directors. The transaction is expected to close by the end of 2026, subject to certain closing conditions.

Kimberly-Clark offers bonds to help fund Tylenol maker takeover. Kimberly-Clark Corp. is looking to help fund its pending acquisition of Kenvue Inc. as it aims to rival Unilever PLC Bloomberg News Brian Smith and Ying Luthra Published Oct 19, 2026 Kimberly-Clark Corp. is selling investment-grade bonds in as many as five parts to help fund its pending acquisition of Tylenol maker Kenvue Inc. The consumer-goods company is offering notes in as many as five parts with maturities of two to 10 years, according to a person with knowledge of the matter, who asked not to be identified because the details are private. Initial price discussions for the longest tenor involve a premium of about one percentage point above U.S. Treasuries, the person added. Story continues below This advertisement has not loaded yet, but your article continues below. Kimberly-Clark held investor calls on Friday, amid a turbulent period for markets. Numerous companies held off on bringing high-grade bond sales last week as Treasury yields swung sharply on stronger-than-expected U.S. inflation data and worries about the artificial-intelligence trade. Canada's best source for investing news, analysis and insight. Interested in more newsletters? Browse here. The Kleenex maker's third-quarter report is due on Nov. 5. Companies typically don't issue bonds in the roughly two-week period before disclosing results. JPMorgan Chase & Co. provided US$7.7 billion in bridge financing late last year to help fund the acquisition. The bond sale is expected to replace that temporary borrowing facility. Other banks managing the bond sale are Citigroup Inc. and Morgan Stanley, the person said. The largely-stock acquisition, expected to close by the end of the year, is currently valued at about US$36 billion. Compensation is set to include US$6.7 billion of cash that would in part come from new debt sales, Kimberly-Clark has previously said. Kenvue has struggled financially since being spun off from Johnson & Johnson in 2023, and the company found itself battling with the Trump administration last year over the safety of its biggest product, Tylenol. Its portfolio also includes Neutrogena lotion, Listerine mouthwash, Benadryl allergy medicine and Band-Aid wound care products. Kimberly-Clark said when the combination was announced last year that buying Kenvue would create a company with US$32 billion in revenue and allow it to surpass Unilever PLC to become the second-biggest seller of health and wellness products after Procter & Gamble Co.